Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

AI detects tumor disease – via voice recording

A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and in...

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

USA upprättar databas över autismpatienter – ska forska kring orsakerna

USA:s hälsomyndigheter ska skapa en databas över autismpatienter för att kunna studera orsakerna till diagnosen. Det meddelade landets hälsominister Robert F. K...

EQT säljer Karo Healthcare för 27 miljarder

Riskkapitalbolaget KKR förvärvar det svenska konsumenthälsobolaget Karo Healthcare från EQT.

BMS planerar investera nära 400 miljarder i USA

Under måndagen meddelade Bristol Myers Squibb att bolaget planerar att investera 40 miljarder dollar, motsvarande 387 miljarder svenska kronor, i USA under de k...

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

The New Precise Magazine is Available Now

Download the new issue.

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Conference recordings now available

Don't miss out on insights from leading experts.

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

Europeiska läkemedelsaktier rasar efter Trumps tullhot

Europeiska läkemedelsbolag faller kraftigt efter att USA:s president Donald Trump flaggat för att stora tullhöjningar är på gång mot branschen.

The Covid pandemic accelerated the development of cancer vaccine

The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast ...

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

Conjugate Planes in Microscopy

Knowledge Article from ZEISS.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

Discover ZEISS ZEN core – now for electron microscopy

Watch the recording of our free webinar.

Lovande resultat för Lillys fetmapiller – skapar börsvågor

Eli Lillys viktminskningspiller överträffar förväntningarna i en fas III-studie och visar resultat i nivå med injicerbara läkemedel som Ozempic. Nyheten fick ak...